Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710500 · ClinicalTrials.gov registry record · Phase 1
rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
A Phase 1 study, sponsored by Sarepta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02710500 is a Phase 1 study that has completed, run by Sarepta Therapeutics. The registered enrollment target is 2 participants.
The verdict
NCT02710500, a Phase 1 study, has completed, sponsored by Sarepta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The proposed clinical trial is a double-blind, randomized controlled study with direct intramuscular injection of rAAVrh.74.MHCK7.DYSF.DV gene vector to the extensor digitorum brevis muscle (EDB). Two cohorts of subjects with dysferlin deficiency, each with proven mutations will undergo gene transfer. A minimum of three subjects will be enrolled into each cohort.
Interventions
- DRUG rAAVrh74.MHCK7.DYSF.DV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02710500
The ClinicalTrials.gov registry entry for NCT02710500 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rAAVrh74.MHCK7.DYSF.DV is the first listed.
NCT02710500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02710500 about?
NCT02710500 is a clinical study titled "rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies". The proposed clinical trial is a double-blind, randomized controlled study with direct intramuscular injection of rAAVrh.74.MHCK7.DYSF.DV gene vector to the extensor digitorum brevis muscle (EDB). Two cohorts of subjects with dysferlin deficiency, each with proven mutations will undergo gene transfe...
What is the current status of trial NCT02710500?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-03. Estimated completion is 2019-07.
What interventions are being tested in trial NCT02710500?
The interventions under investigation include: rAAVrh74.MHCK7.DYSF.DV (DRUG).
Who is sponsoring clinical trial NCT02710500?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.